[{"orgOrder":0,"company":"Celerion","sponsor":"Neuropore Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Neurology","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Prometheus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"}]

Find Clinical Drug Pipeline Developments & Deals by MTS Health Investors, LLC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : PRA023, the company's lead product candidate, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A).

                          Brand Name : PRA023

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 03, 2021

                          Lead Product(s) : PRA023

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Recipient : Prometheus Biosciences

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.

                          Brand Name : NPT520-34

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 13, 2020

                          Lead Product(s) : NPT520-34

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Recipient : Neuropore Therapies

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank